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Invariant natural killer T (iNKT) cells are a distinct lineage of αβ T lymphocytes with the capacity to recognize 
glycolipid antigens in the context of the atypical major histocompatibility complex (MHC) class I molecule 
CD1d. In response to engagement of the T cell receptor (TCR), iNKT cells efficiently and rapidly produce a 
broad range of cytokines and several chemokines. iNKT cells participate in a variety of immune responses 
through cross-talk with many other innate and adaptive immune cells, including dendritic cells (DCs), natural 
killer (NK) cells, conventional CD4+ T cells, CD8+ T cells, B cells, neutrophils and regulatory T cells. Despite a 
relatively restrictive diversity in their TCR, these cells respond to vastly diverse microbial pathogens. The 
mechanisms underlying activation of iNKT cells at the maternal-fetal interface in inflammation-induced preterm 
delivery is not fully understood. In a recent study, we investigated which specific pathways were involved in 
decidual iNKT cell activation in a model for lipopolysaccharide (LPS)-stimulated preterm delivery. To do this, 
we employed an adoptive transfer system in combination with a diverse array of neutralizing antibodies (Abs) 
and inhibitors. We demonstrated that the activation of decidual iNKT cells requires TLR4-mediated nuclear 
factor-κB (NF-κB), mitogen-activated protein kinase (MAPK) p38 and extracellular signal-regulated kinase 
(ERK) pathways, the proinflammatory cytokines IL-12 and IL-18, and endogenous glycolipid antigens presented 
by CD1d. Our findings give new insights into the molecular mechanisms underlying iNKT cell activation during 
microbial infection as well as the role of iNKT cells in preterm delivery induced by inflammation. These findings 
underscore the promise that iNKT cell-based immunotherapies that target specific pathways utilized during 
iNKT cell activation could advance our ability to treat iNKT cell-associated inflammatory diseases, including 
preterm delivery. 
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Natural killer T (NKT) cells are a unique subset of T cells 
that have been described as one of the most potent 
modulators of innate and adaptive immunity [1]. While 
conventional T cells recognize peptide antigens presented by 
major histocompatibility complex (MHC) class I or II 
proteins, NKT cells specifically recognize glycolipid 
antigens presented by the MHC class I-like antigen 
presenting molecule CD1d [2]. CD1d-restricted NKT cells are 
subcategorized by their T cell receptor (TCR) repertoire and 
antigenicity profile into type I and type II NKT cells. To date, 
the best characterized NKT cells are type I or invariant NKT 
(iNKT) cells. The semi-invariant TCR expressed on these 
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cells is comprised of an invariant TCR α chain (Vα14-Jα18 
in mice and the homologous Vα24-Jα18 in humans) that 
pairs with a limited selection of TCR β chains (Vβ8.2, Vβ7 
or Vβ2 in mice and Vβ11 in humans) [3]. It is notable that 
iNKT cells can very rapidly produce a wide array of 
cytokines in response to TCR engagement, including 
interferon (IFN)-γ, interleukin (IL)-2, IL-3, IL-4, IL-5, IL-6, 
IL-9, IL-10, IL-13, IL-17, IL-21, granulocyte-macrophage 
colony-stimulating factor (GM-CSF), tumor necrosis factor 
(TNF)-α, and several chemokines, including regulated upon 
activation normal T cells expressed and secreted (RANTES) 
and macrophage inflammatory protein-1α (MIP-1α) [4]. In a 
feed-forward fashion, activated iNKT cells can augment the 
immune response they initiated by stimulating other immune 
cells types, including dendritic cells (DCs) [5], natural killer 
(NK) cells [6], conventional CD4+ T cells [7], CD8+ T cells [8], 
B cells [9], neutrophils [10] and CD4+CD25+ regulatory T cells 
[11]. The ability of iNKT cells to utilize cytokine and 
chemokine-mediated mechanisms to modulate both innate 
and adaptive immunity highlights their central role in 
immune responsivity. iNKT cells also express high levels of 
granzyme B, perforin and Fas ligand (FasL), products 
consistent with direct and indirect involvement in cytolysis 
[12]. It is these unique properties that allow iNKT cells to 
regulate host defense responses and immune-related 
protection and pathology, including microbial immunity [13, 
14], tumor immunity [15], autoimmunity [16, 17] and 
transplantation immunity [18]. 
Preterm delivery, defined as delivery occurring before 37 
weeks’ gestation, accounts for more than 12% of all births in 
the United States [19]. The prevalence of preterm delivery is 
increasing despite major advances in obstetric and neonatal 
care [20]. Preterm delivery is a major international challenge, 
accounting for at least 1 million perinatal and pediatric 
deaths, and is the single most significant contributor to 
perinatal and pediatric morbidity and mortality worldwide [21]. 
Infection is the leading cause of preterm delivery. In fact, 
infection of the gestational compartment is found in nearly 
40% of cases of preterm delivery [22]. Maternal infection has 
been shown to stimulate immune responses through signaling 
events initiated by cell surface recognition molecules such as 
Toll-like receptors (TLRs) [23]. Ligand binding of TLR4 
stimulates host inflammatory responses and is central to the 
pathogenesis of infection-associated preterm delivery [24]. 
In a recent study [25], we employed decidual iNKT cell 
adoptive transfer to elucidate the role of iNKT cells in 
lipopolysaccharide (LPS)-induced preterm delivery. There 
are two common ways to model LPS-induced preterm 
delivery in animals. They have important differences. One 
models localized intrauterine infection and involves 
anesthesia, laparotomy, and intrauterine injection of LPS [26]. 
The other models maternal systemic infection and involves 
intraperitoneal administration of LPS [27]. The localized 
inflammation model is thought to more closely mimic the 
clinical presentation of infection-related preterm delivery 
when compared to the systemic infection model and results 
in minimal maternal mortality and much more limited 
Figure 1. Protocol for the LPS-induced preterm delivery model and adoptive 
transfer of decidual iNKT cells. (A) Pregnant WT Jα18+/+ mice or Jα18 KO mice 
were i.p. injected with LPS (100 μg/kg body weight) or PBS on day 15 of gestation. 
(B) Jα18-/- mice were injected with decidual iNKT cells from WT C57BL/6 mice 2 h 
prior to LPS or PBS injection on day 15 of gestation. 
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maternal morbidity [26]. However, the involvement of 
surgical induction of the disease state is more complicated 
than mere i.p. injection, takes longer than the induction of the 
systemic inflammation model, and the required anesthesia 
and surgery does affect the dams in ways that may not be 
fully understood. Further, the sterile inflammation caused by 
the laparotomy may promote preterm delivery, although both 
effects may be mimicked in control animals that undergo 
sham operation. In contrast, while intraperitoneal injection of 
LPS is an effective and methodologically easy way to induce 
preterm delivery, maternal morbidity and even mortality are 
higher than that after surgical induction of local 
inflammation. That said, for our investigations, we 
successfully established a modified and less morbid murine 
model of preterm delivery that involved intraperitoneal 
injection of LPS (100 mg/kg body weight) on d15 of 
gestation. This i.p. LPS dosage and timing, while sufficient 
to induce preterm delivery, is accompanied by essentially no 
maternal mortality or detectable maternal morbidity.  
The transgenic mice used in our study were Jα18 knockout 
(KO) mice. These animals are characterized by a deficiency 
in iNKT cells. Vα14 NKT cells express a single invariant 
TCR α chain encoded by the Vα14 and the Jα18 segments [3].  
Conventional T cells do not express this TCR α chain. It is 
this unique expression of the invariant Vα14 TCR that allows 
specific deletion of the Jα18 gene to result in a selective loss 
of CD1d-dependent Vα14 NKT cells without affecting the 
other lymphoid lineages [28]. The development of the 
lymphoid organs in Jα18-/- mice is normal at a macroscopic 
level. Further, other than the complete loss of the Vα14 NKT 
cells, the numbers of local and circulating lymphocytes are 
very similar to those in wild type (WT) Jα18+/+ mice [28].  
Jα18-/- mice are known to be fertile and otherwise healthy [29].  
The schematic protocol used in our investigations for the 
induction of preterm delivery and adoptive transfer of 
decidual iNKT cells is shown in Fig. 1. Our data showed that 
iNKT cell depletion significantly decreased preterm delivery 
in mice subjected to intraperitoneal administration of LPS. 
Figure 2. Effects of iNKT cells on LPS-induced preterm birth. (A) LPS treatment significantly increased preterm 
birth in WT mice, while deficiency of iNKT cells in Jα18 KO animals decreased LPS-induced preterm birth. (B) 
Adoptive transfer of decidual iNKT cells from WT mice into Jα18-/- mice significantly up-regulated preterm birth upon 
LPS stimulation, while adoptive transfer of decidual iNKT cells into Jα18-/- mice treated with PBS did not affect 
preterm birth. 
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This suggests an important role for iNKT cells in 
LPS-induced preterm delivery. In addition, adoptive transfer 
of decidual iNKT cells into LPS-stimulated Jα18 KO mice 
from WT mice markedly increased preterm delivery, 
confirming the role of decidual iNKT cells in inflammatory 
preterm delivery (Fig. 2A). In contrast, transfer of donor 
decidual iNKT cells had no effect on the time to delivery in 
PBS-treated Jα18-/- mice. This supports the concept that 
exposure to these allogeneic cells will not, on its own, 
promote preterm delivery (Fig. 2B). In order to further 
explore the mechanisms underlying decidual iNKT 
cell-mediated preterm delivery, we assessed the percentages 
of decidual iNKT cells in recipient Jα18-/- mice. Adoptive 
transfer of decidual iNKT cells notably increased the 
percentage of decidual iNKT cells in LPS-exposed mice but 
not in PBS-treated Jα18-/- mice. This result suggested that 
LPS-induced systemic inflammation promotes iNKT cell 
migration to the recipient decidua. Further, donor decidual 
iNKT cell-mediated increases in preterm delivery may occur 
as the result of increases in the percentage of recipient 
decidual iNKT cells. 
iNKT cells are powerful protective components in the host 
defense response to a  considerable variety of microbial 
pathogens. Despite a markedly restricted TCR repertoire, 
these cells respond rapidly to a diverse array of microbial 
pathogens and display integral innate-like immune cell 
characteristics. iNKT cell activation appears to occur via two 
distinct pathways. One is a direct, microbial antigen-driven 
pathway. Some microbial glycolipids, such as 
glycosphingolipids (GSLs) from Sphingomonas [30, 31] and 
diacylglycerols from Borrelia burgdorferi, Ehrlichia and 
Streptoccus pneumonia [32, 33], can directly activate iNKT 
cells through the TCR. The other is TCR-independent and 
indirect. NKT cells can also respond to proinflammatory 
cytokines, such as IL-12, IL-18 or type I IFNs produced by 
antigen presenting cells upon TLR stimulation. This can be 
accomplished with [30, 34-36] or without [37-39] an 
accompanying weak TCR-mediated signal provided by 
recognition of CD1d-presented self-antigens. 
The indirect pathway of iNKT cell activation was first 
described for the Gram-negative, LPS-positive microbe, 
Salmonella typhimurium [34]. Study of the pathogenesis of 
this infection revealed that IL-12 made by DCs in response to 
microbial products augments weak responses to 
CD1d-presented self-antigens and this, in turn, stimulates 
substantial IFN-γ secretion [34]. It has also been shown that 
Salmonella can trigger iNKT cells through the presentation 
of an endogenous lysosomal GSL, iGb3, by LPS-activated 
DCs [30]. In contrast, it has been reported that Escherichia 
coli LPS and Salmonella abortus equi LPS can activate 
iNKT cells through processes dependent on cytokines but 
independent of CD1d [37]. iNKT cell secretion of IFN-γ was 
not dependent on presentation of an endogenous antigen by 
CD1d in these studies. Instead, activation and IFN-γ 
secretion could be fully realized via culture in the presence of 
both IL-12 and IL-18.  
Others have shown that iNKT cells can be activated in 
vitro or in vivo by an array of TLR agonists, including 
agonists of TLR2, TLR3, TLR5, TLR7, TLR8 and TLR9 [35, 
36, 38, 39]. CpG oligodeoxynucleotides (ODN) and mouse 
cytomegalovirus (MCMV), which signal via TLR9, can 
stimulate iNKT cells to secrete IFN-γ but not IL-4. Also 
proposed is a requirement for DC-mediated type I IFN 
synthesis and de novo production of charged beta-linked 
GSLs in order for iNKT cell to be fully activated after 
ligation of TLR9 [35]. Still others have reported that this 
reaction only requires IL-12 and/or IFN-α/β secretion, but 
not CD1d expression [38, 39]. Furthermore, it has been 
demonstrated that iNKT cell IFN-γ production in response to 
in vitro stimulation or infection with a variety of bacterial 
species overwhelmingly depends on TLR-driven IL-12. Even 
Figure 3. Protocol for the administration of neutralizing Abs and inhibitors. WT 
C57BL/6 mice were injected with neutralizing Abs against TLR4, CD1d, IL-12 and 
IL-18, or inhibitors blocking the activation of p38, ERK, JNK and NF-κB on day 11 and 
day 13 of gestation, and then injected with LPS on day 15 of gestation.  
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pathogens such as Sphingomonas yanoikuyae and 
Streptococcus pneumoniae that both require iNKT cells for 
optimal protection and express iNKT cell antigens can 
activate iNKT cells via mechanisms that mainly rely on 
IL-12. Together, these studies support the concept that iNKT 
cell activation during microbial infections is primarily driven 
by innate and cytokine-mediated signals and not by cognate 
microbial antigen [40]. 
In our study [25], we wanted to leverage the murine model 
of LPS-induced preterm delivery and a defined set of 
canonical neutralizing antibodies and inhibitors of specific 
steps involved in TLR4 signaling to better define specific 
underlying pathways involved in decidual iNKT cell 
activation. The antibodies and inhibitors were explicitly 
chosen to cover the full extent of the LPS signaling pathway, 
from initial ligand recognition and engagement of CD1d to 
the production and secretion the immune effector molecules, 
IL-12 and IL-18 (Fig. 3). Most of the inhibitory exposures 
utilized were demonstrated to markedly decrease readouts of 
LPS activity, including in vivo percentages of decidual iNKT 
cells, expression of CD69 and production of intracellular 
IFN-γ, as well as in vitro expression of CD69 on decidual 
iNKT cells and intracellular and extracellular secretion of 
IFN-γ in response to LPS (Fig. 4). Included among these 
proven inhibitory exposures were: 1) an inhibitor of 
mitogen-activated protein kinase (MAPK) p38, 2) an 
inhibitor of nuclear factor-κB (NF-κB) activation, 3) an 
inhibitor of extracellular signal-regulated kinase (ERK), 4) 
an anti-TLR4 neutralizing antibody, 5) an anti-IL-12 
neutralizing antibody and 6) an anti-IL-18 neutralizing 
antibody (Fig. 4). Somewhat surprisingly, blockade of c-Jun 
N-terminal kinase (JNK) had no appreciable effect on the 
activation decidual iNKT cells (Fig. 4). Collectively, we 
were able to show that Escherichia coli LPS-induced 
decidual iNKT cell activation utilizes TLR4-mediated 
downstream ERK and NF-κB, p38 pathways and both IL-12- 
and IL-18-mediated signaling. Moreover, we proved that, 
while the IL-12 and IL-18 were each necessary for decidual 
iNKT cells activation, neither was sufficient. Further, IL-12 
and IL-18, in combination, demonstrate synergism in their 
stimulatory effects on IFN-γ production by decidual iNKT 
cells. 
It is known that CD1d-restricted iNKT cells are able to 
recognize a remarkably wide assortment of endogenous and 
exogenous lipid and glycolipid antigens [41]. In the thymus, 
CD1d-restricted recognition of endogenous glycolipid 
antigens is central to the appropriate selection and 
development of iNKT cells [42]. Moreover, the auto-reactivity 
of iNKT cells promotes a modified basal level of activation 
that enables suitable responses to subsequent co-stimulatory 
cytokines in the absence of the necessity for concurrent TCR 
stimulation [43]. The question of whether indirect activation 
of iNKT cells requires TCR-mediated signals generated after 
recognition of CD1d-presented endogenous glycolipids 
continues to be disputed. In our study, exposure to an 
antibody directed against CD1d reduced decidual iNKT cell 
percentages as well as their production of intracellular and 
extracellular IFN-γ and expression of surface CD69 upon 
LPS stimulation, all in the absence of exogenous antigens. 
These findings suggest that decidual iNKT cell activation is 
also contingent upon TCR stimulation by endogenous 
glycolipids presented by CD1d. 
LPS has been reported to alter the synthesis of GSLs in a 
monocyte cell line [44]. This could increase presentation of 
glycolipid-derived self-antigens. Additionally, pretreatment 
Figure 4. Effects of neutralizing Abs and inhibitors on LPS-induced preterm delivery. 
Neutralizing Abs against TLR4, IL-12, IL-18 and CD1d, or antagonists of p38, ERK and NF-κB 
markedly decreased LPS-mediated activation of decidual iNKT cells, while JNK inhibitor had no 
effect on inflammation-induced activation of decidual iNKT cells. 
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of DCs with N-butyl-deoxygalactonojirimycin (NB-DGJ), an 
inhibitor of β-D-glucopyranosylceramide (β-GlcCer) 
synthase, markedly reduces the ability of CpG 
ODN-stimulated DCs (or lipids extracted from these cells) to 
activate iNKT cells [35]. This is strong evidence that DCs 
produce charged β-GlcCer-derived GSLs in response to CpG 
ODN and that, together with type I IFNs, these GSLs can 
stimulate iNKT cells.  
The TLR8 ligand R848 has been shown to enhance or 
alter the synthesis of GSLs and this contributes to the iNKT 
cell activation status [36, 43]. Moreover, β-GlcCer has been 
proposed as a potent iNKT cell self-antigen in mice and 
humans, and has been shown to contribute to iNKT cell 
activation in response to TLR agonists [45]. The identity of 
the subset of glycolipids directly involved in the physiologic 
stimulation of iNKT cells as opposed to those involved in 
iNKT cell activation in the presence of microbial infection 
remains undefined. The likelihood that endogenous 
glycolipids are involved but not yet identified provides yet 
another important aspiration for iNKT cell biologists.  
In summary, our recent demonstration that TLR4- 
mediated pathways and IL-12 and IL-18 secretion in 
combination with autoantigenic TCR signaling are centrally 
involved in the activation of decidual iNKT cells by LPS 
adds to a growing body of literature suggesting an integral 
role for activated iNKT cells at the maternal-fetal interface in 
infection-associated preterm delivery [25, 46]. The indirect 
pathway of decidual iNKT cell activation may be particularly 
important in this respect, as it endows these cells with the 
ability to respond rapidly to a wide variety of microbes 
despite a limited TCR diversity, and thereby modulates 
inflammatory reactions at the maternal-fetal interface. 
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